Georgia's Online Cancer Information Center

Find A Clinical Trial

A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects With Relapsed or Refractory Haematologic Malignancies

Status
Active
Cancer Type
Hodgkin Lymphoma
Leukemia
Lymphoma
Multiple Myeloma
Myelodysplastic Syndromes (MDS)
Non-Hodgkin Lymphoma
Skin Cancer (Non-Melanoma)
Unknown Primary
Trial Phase
Phase I
Eligibility
18 to 85, Male and Female
Study Type
Treatment
NCD ID
NCT03218683
Protocol IDs
D6910C00001 (primary)
NCI-2017-01390
Study Sponsor
AstraZeneca Pharmaceuticals LP

Summary

This study is a multicenter, open-label, nonrandomized, sequential group, dose-escalation

study to assess safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of

ascending doses of AZD5991 in subjects with relapsed or refractory hematologic malignancies.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University


1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.